Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Hibiscus rosa-sinensis Linn as an Excipient in Sustained-Release Tablets
Natural gums and mucilage are biocompatible, cheap, readily available, and represent a potential source of excipients. The authors examine the functionality of mucilage extracted from the leaves of Hibiscus rosa-sinensis Linn as an excipient in a sustained-release tablet formulation.


Pharmaceutical Technology
Volume 32, Issue 1

30. P.D. Fowler et al., "Plasma and Synovial Fluid Concentration of Diclofenac Sodium and its Major Hydroxylated Metabolites During Long-term Treatment of Rheumatoid Arthritis," Eur. J. Clin. Pharmacol. 25 (3), 389–394 (1983).

31. J.V. Willis, M.J. Kendall, and D.B. Jack, "The Influence of Food on the Absorption of Diclofenac After Single and Multiple Oral Doses," Eur. J. Clin. Pharmacol. 19 (1), 33–37 (1981).

32. S.P. Wahi et al. "Studies on Suspending Property of Mucilage of Hygrophila Spinosa T. Anders and Hibiscus Esculentus Linn," Indian Drug. 22 (9), 500–502 (1985).

33. F.E. Bowen and W.A. Vadino, "A Simple Method for Differentiating Starches," Drug Dev. Ind. Pharm. 10, 505–511 (1984).

34. L. Lachman, H.A. Libermann, and J.L. Kanig, The Theory and Practice of Industrial Pharmacy (Varghese Publishing House, Bombay, India, 3d ed., 1987), p. 318.

35. D. Thomas and F. Reza, "Guar Based Monolithic Matrix Systems: Effect of Ionizable and Non-ionizable Substances and Excipients on Gel Dynamics and Release Kinetics," J. Controlled Release 80 (1–3), 45–56 (2002).

36. P. Colombo et al., "Drug Release Modulation by Physical Restriction of Matrix Swelling," Int. J. Pharm. 63 (1), 43–48 (1990).

37. M. Bamba and F. Puisieux, "Release Mechanisms in Gel Forming Sustained Release Preparations" Int. J. Pharm. 2, 307-315 (1979).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here